Tredje AP fonden Sells 53 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Tredje AP fonden lessened its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 1.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,367 shares of the medical research company’s stock after selling 53 shares during the quarter. Tredje AP fonden’s holdings in Bio-Rad Laboratories were worth $920,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Van ECK Associates Corp acquired a new position in shares of Bio-Rad Laboratories during the 2nd quarter worth about $180,040,000. Norges Bank acquired a new position in shares of Bio-Rad Laboratories during the fourth quarter worth approximately $73,142,000. Dimensional Fund Advisors LP boosted its position in shares of Bio-Rad Laboratories by 64.4% in the second quarter. Dimensional Fund Advisors LP now owns 494,604 shares of the medical research company’s stock valued at $135,081,000 after acquiring an additional 193,700 shares during the period. Parsifal Capital Management LP bought a new stake in shares of Bio-Rad Laboratories in the fourth quarter valued at approximately $61,866,000. Finally, Earnest Partners LLC grew its stake in shares of Bio-Rad Laboratories by 30.8% in the first quarter. Earnest Partners LLC now owns 514,906 shares of the medical research company’s stock worth $178,091,000 after acquiring an additional 121,272 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on BIO shares. Royal Bank of Canada reissued an “outperform” rating and issued a $401.00 price target on shares of Bio-Rad Laboratories in a report on Friday, August 16th. Jefferies Financial Group reissued a “hold” rating and set a $315.00 target price (down from $440.00) on shares of Bio-Rad Laboratories in a research report on Monday, June 3rd. Citigroup boosted their price target on Bio-Rad Laboratories from $300.00 to $350.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price objective for the company. Finally, StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of “Hold” and an average target price of $358.20.

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock opened at $329.99 on Friday. The firm has a market capitalization of $9.41 billion, a P/E ratio of -31.85 and a beta of 0.95. The stock has a fifty day moving average price of $323.25 and a two-hundred day moving average price of $307.87. Bio-Rad Laboratories, Inc. has a 52-week low of $261.59 and a 52-week high of $366.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.28 and a quick ratio of 4.63.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, August 1st. The medical research company reported $3.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.99. The business had revenue of $638.50 million during the quarter, compared to analysts’ expectations of $645.79 million. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.77%. The firm’s revenue for the quarter was down 6.3% on a year-over-year basis. During the same quarter last year, the company posted $3.00 EPS. As a group, analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.31 EPS for the current fiscal year.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the transaction, the chief operating officer now directly owns 7,559 shares in the company, valued at $2,494,016.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP James Barry sold 623 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the transaction, the executive vice president now owns 147 shares of the company’s stock, valued at approximately $48,582.03. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the sale, the chief operating officer now owns 7,559 shares of the company’s stock, valued at approximately $2,494,016.46. The disclosure for this sale can be found here. Corporate insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.